CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
ZW25drug
Likely dose
ZW25 20mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04513665
NCT04513665Phase 2Completed
CompareCT.gov

A Phase 2 Trial of ZW25 in HER2 Overexpressed Advanced Endometrial Cancers and Carcinosarcomas (ZW25-IST-2)

Memorial Sloan Kettering Cancer Center·interventional·Posted Aug 14, 2020·Updated May 22, 2025

In Brief

A Phase 2 clinical trial evaluating ZW25 for Endometrial Cancer and Carcinosarcoma. Completed, enrolled 16 participants across 7 sites.

Detailed Summary

This study is being done to test the drug ZW25 and look at whether this drug is effective in women with HER2-overexpressed endometrial cancer or carcinosarcoma that has been treated in the past.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Cancer, Carcinosarcoma
CountriesUnited States
CollaboratorsZymeworks BC Inc.

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedAug 14, 2020
Enrollment StartAug 12, 2020
Primary CompletionMar 8, 2024
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 5.9 years ago

Interventions

ZW25drug

ZW25 at 20mg/kg intravenously (IV) every two weeks.